Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) has shared an announcement.
Jiangsu Recbio announced that China’s Center for Drug Evaluation has officially accepted the new drug application for its novel adjuvanted recombinant shingles vaccine REC610, which uses the company’s proprietary BFA01 adjuvant to boost VZV gE-specific cellular and antibody responses. The candidate has completed subject enrolment for a Phase III trial in adults aged 40 and above and showed favourable safety and strong immune responses comparable to GlaxoSmithKline’s Shingrix in exploratory head-to-head studies in China and the Philippines, underscoring its potential to address a sizeable shingles market in China, though the company cautions there is no assurance REC610 will ultimately be successfully developed or commercialised.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a Chinese biopharmaceutical company focused on the research, development and commercialization of novel vaccines, including adjuvanted recombinant products. Its pipeline targets significant infectious diseases such as shingles, addressing large and growing patient populations in China and competing with leading global vaccine brands.
Average Trading Volume: 56,306
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.25B
See more insights into 2179 stock on TipRanks’ Stock Analysis page.